Indications
Lyfnua is indicated in adults for the treatment of refractory or unexplained chronic cough.
Composition
- Active substance
- gefapixant
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Lyfnua
- Active substance
- gefapixant
- ATC code
- R05DB29
- Group
- Respiratory system
- Therapeutic area
- Cough
- Marketing authorisation holder
- Merck Sharp & Dohme B.V.
- Status
- Authorised
- EU authorisation
- 15 Sept 2023
- EMA product number
- EMEA/H/C/005476